among
myriad
hypothes
mechan
hcv
persist
role
escap
mutat
controversi
anoth
seri
eleg
studi
freiburg
fratern
convincingli
shown
restrict
epitop
site
intens
immun
pressur
import
hcv
clearanc
mani
group
look
hla
associ
hcv
infect
identifi
end
studi
unconvinc
statist
associ
cowork
taken
us
step
previous
note
outbreak
hepat
c
among
german
women
receiv
contamin
globulin
recoveri
infect
significantli
associ
current
studi
investig
identifi
restrict
epitop
show
women
clear
hcv
infect
mount
strong
respons
one
epitop
region
epitop
studi
patient
chronic
infect
rh
cohort
respons
common
recov
subject
chronic
patient
differ
signific
p
importantli
chronic
infect
show
sequenc
variat
domin
site
far
excess
observ
neg
subject
p
lo
alamo
databas
p
recov
infect
result
suggest
chronic
infect
patient
experienc
select
pressur
viral
region
evolv
escap
variant
studi
thu
nice
link
two
observ
associ
recoveri
hcv
infect
evolut
critic
escap
mutat
patient
chronic
infect
author
also
show
line
chronic
infect
patient
function
impair
variant
peptid
compar
intrahepat
cell
find
togeth
prior
studi
chimpanze
pna
j
exp
med
human
j
exp
med
reinforc
critic
role
escap
variant
persist
hcv
infect
import
role
certain
particularli
foster
recoveri
see
hepatolog
seek
chees
better
cure
rate
levi
et
al
develop
clever
mousetrap
primari
limit
ribavirin
therapi
hemolyt
anemia
occur
degre
treat
patient
studi
attempt
limit
exposur
red
cell
free
ribavirin
target
ribavirin
directli
liver
approach
found
fact
free
hemoglobin
rapidli
bound
haptoglobin
complex
taken
kupffer
cell
hepatocyt
trough
scaveng
receptor
investig
develop
conjug
acellular
hemoglobin
hb
haptoglobin
hp
ribavirin
design
hrc
multipl
ribavirin
molecul
conjug
hemoglobin
molecul
enhanc
potenti
higher
intracellular
concentr
bind
uptak
hrc
alreadi
demonstr
model
cell
express
receptor
lysosom
enzym
shown
releas
bioactiv
ribavirin
hrc
vitro
trap
enter
mice
inocul
mous
coronaviru
replic
macrophag
invad
liver
viral
infect
character
massiv
respons
sever
hepat
necrosi
fulmin
hepat
failur
occur
within
day
infect
lead
death
infect
mice
initi
studi
investig
examin
effect
hrc
viral
replic
macrophag
isol
hepatocyt
wherea
free
ribavirin
effect
replic
dose
util
lower
dose
hrc
result
reduct
viral
replic
respect
hrc
inhibit
product
compar
free
ribavirin
experi
serv
prelud
assess
effect
hrc
experiment
infect
mice
studi
involv
mice
per
group
control
mice
massiv
alt
elev
altmax
iul
die
within
day
compar
mice
altmax
surviv
hrc
mice
altmax
surviv
although
signific
differ
altmax
surviv
free
ribavirin
hrc
viral
titer
ribavirin
group
twofold
higher
hrc
group
p
anim
clinic
symptom
fall
hematocrit
elev
bun
wherea
hrc
mice
symptom
free
maintain
normal
hematocrit
bun
mous
hole
studi
obvious
main
caveat
inde
mice
human
viru
treat
rna
viru
quit
distinct
hcv
nonetheless
concept
conjug
ribavirin
facilit
receptor
mediat
target
quit
sound
implic
studi
previous
highlight
studi
escal
ribavirin
dosag
hepatolog
ribavirin
better
high
concentr
achiev
without
limit
toxic
conjug
normal
human
protein
establish
macrophag
liver
receptor
mechan
clever
ration
approach
believ
find
way
clinic
trial
may
find
hole
chees
put
definit
test
human
optimist
work
shut
trap
see
hepatolog
studi
bortolotti
et
al
repres
final
report
longitudin
homogen
popul
hbv
genotyp
caucasian
children
padova
itali
prospect
provid
import
insight
hbv
infect
children
spread
horizont
rather
matern
transfer
also
address
outcom
caucasian
popul
rather
frequent
studi
eman
asia
overal
studi
speak
rel
benign
hbv
infect
acquir
manner
young
age
investig
follow
hbsaghbeag
hbsag
children
fig
among
hbeag
lost
remain
lost
hbeag
seroconvers
cirrhosi
present
without
cirrhosi
classifi
inact
carrier
hepat
mean
year
inact
carrier
reactiv
develop
persist
though
gener
hepat
interestingli
initi
cirrhosi
lost
histolog
featur
cirrhosi
reach
adulthood
two
develop
small
resect
carcinoma
still
live
cirrhosi
initi
inact
carrier
hepat
end
initi
hbeag
lost
hbeag
also
hbsag
hbv
dna
suggest
true
recoveri
thu
well
defin
care
follow
cohort
seriou
outcom
three
decad
percentag
similar
children
young
adult
infect
hcv
age
infect
appear
critic
determin
outcom
agent
unansw
question
agent
whether
stabl
benign
infect
might
exacerb
rel
immunodefici
age
intercurr
immunosuppress
diseas
treatment
also
unansw
whether
one
acquir
horizont
infect
stand
see
hepatolog
last
quarter
hepatolog
issu
three
independ
studi
examin
cofactor
predictor
progress
fibrosi
includ
influenc
coexist
schistosomiasi
steatosi
multipl
factor
associ
ivdu
concomit
schistosomiasi
hcv
shown
previous
run
rapid
sever
histolog
cours
respond
poorli
interferon
studi
calcul
rate
progress
fibrosi
markedli
greater
coinfect
popul
compar
patient
p
point
clinic
interest
includ
hcv
rna
level
significantli
higher
patient
coinfect
mansoni
copml
vs
copml
p
end
coinfect
patient
splenomegali
esophag
varic
compar
hcv
monoinfect
progress
fibrosi
stage
greater
seen
patient
schistosomiasi
compar
none
hcv
monoinfect
group
howev
miss
studi
third
arm
patient
schistosomiasi
mani
would
sever
outcom
portal
hypertens
even
absenc
hcv
effect
hcv
schistosomiasi
mere
addit
synergist
effect
lead
exponenti
progress
fibrosi
nonetheless
drastic
outcom
make
appear
schistosomiasi
may
detriment
cofactor
hcv
fibrosi
progress
surpass
alcohol
hbv
hiv
nash
given
strike
differ
progress
fibrosi
investig
abl
compar
predictor
fibrosi
prospect
studi
marker
fibrosi
analyz
serum
liver
also
known
human
cartilag
glycoprotein
hc
propeptid
collagen
iii
piiinp
level
marker
compar
cohort
entri
first
year
infect
coinfect
patient
sharp
increas
serum
begin
year
marker
particularli
correl
strongli
progress
fibrosi
r
fig
also
strong
correl
serum
level
hepat
mrna
express
confirm
hepat
origin
util
serum
measur
combin
experiment
valid
cohort
analysi
patient
without
diseas
progress
increas
patient
progress
diseas
fail
increas
level
sensit
specif
overal
power
studi
inde
helminth
studi
make
strong
case
use
predictor
progress
fibrosi
marker
specif
collagen
deposit
matrix
format
valid
establish
prospect
intrins
appeal
mani
indirect
predict
marker
princip
distinguish
cirrhosi
mild
diseas
adequ
assess
stage
lead
cirrhosi
see
hepatolog
perumalswami
et
al
examin
computer
patholog
databas
nih
assess
influenc
steatosi
progress
fibrosi
patient
chronic
hepat
c
predominantli
white
male
genotyp
steatosi
observ
classifi
moder
sever
steatosi
multivari
analysi
steatosi
significantli
associ
older
age
high
bmi
alt
level
fibrosi
among
patient
two
liver
biopsi
progress
fibrosi
progress
correl
baselin
level
steatosi
p
chang
steatosi
score
correl
chang
fibrosi
score
p
ns
lack
associ
fibrosi
steatosi
conflict
previous
publish
data
suggest
effect
steatosi
depend
popul
studi
sever
steatosi
perhap
whether
steatosi
simpli
obes
relat
part
metabol
syndrom
studi
less
diabet
insulin
resist
measur
alcohol
infrequ
left
conclud
either
steatosi
per
se
relev
progress
fibrosi
fibrogen
influenc
steatosi
depend
etiolog
extent
steatosi
thu
patient
associ
steatosi
fibrosi
studi
steatosi
may
red
her
albeit
fat
red
her
interplay
hcv
obes
metabol
syndrom
hepat
steatosi
cytokin
oxid
stress
inflamm
fibrosi
complex
synthes
model
yet
evid
basic
problem
fat
still
larg
someth
chew
see
hepatolog
wilson
cowork
taken
anoth
look
baltimor
ivdu
cohort
examin
progress
fibrosi
pair
liver
biopsi
obtain
mean
interv
year
averag
estim
durat
infect
dogma
ivdu
fare
badli
continu
exposur
concomit
alcohol
coexist
infect
particularli
hbv
hiv
cohort
done
surprisingli
well
despit
fact
male
hbv
infect
heavi
drinker
baselin
biopsi
modifi
ishak
fibrosi
score
greater
year
progress
fibrosi
increas
unit
cirrhosi
overal
estim
year
infect
mild
fibrosi
hai
inflammatori
score
less
author
focus
predictor
progress
fibrosi
progress
observ
often
higher
hcv
rna
level
higher
alt
ast
gtt
level
baselin
howev
progress
fibrosi
normal
aminotransferas
low
hcv
rna
level
progress
fibrosi
associ
gender
age
lifetim
recent
alcohol
use
frequenc
ivdu
steatosi
bmi
perhap
surpris
progress
fibrosi
increas
hiv
infect
possibl
explain
fact
count
exclud
studi
multivari
logist
regress
analysi
hcv
rna
level
log
copiesml
alt
baselin
signific
predictor
fibrosi
outcom
p
respect
publish
predictor
fibrosi
fibrosur
apri
predict
fibrosur
apri
score
predict
progress
respect
develop
signific
fibrosi
interv
studi
ppv
contrast
algorithm
predict
insignific
fibrosi
sensit
even
might
spuriou
given
low
overal
prevalenceincid
fibrosi
cohort
bottom
line
studi
seem
despit
multipl
factor
favor
develop
fibrosi
ivdu
cohort
similar
rate
sever
fibrosi
gener
year
result
might
neg
factor
amelior
rel
young
age
cohort
high
proport
african
american
balanc
mean
outcom
might
logic
predict
logic
predictor
work
studi
see
hepatolog
cyclosporin
csa
amino
acid
cyclic
peptid
potent
immunosuppress
activ
less
recogn
fact
potent
inhibitor
hiv
replic
also
activ
schistosoma
plasmodium
recent
csa
also
shown
inhibit
hcv
replic
vitro
enhanc
ifn
therapi
small
clinic
trial
problem
csa
immunosuppress
effect
head
better
live
chemistri
cyclosporin
develop
primari
modif
compound
calcineurin
bind
domain
region
critic
immunosuppress
effect
seri
eleg
studi
involv
sever
hcv
replicon
infecti
clone
paeshuys
et
al
show
potent
inhibitori
activ
hcv
significantli
exce
csa
vitro
studi
plu
interferon
addit
synergist
effect
shown
consist
differ
mode
action
studi
shown
activ
greater
csa
thu
tempt
think
drug
might
particularli
use
treat
combin
infect
postul
mechan
activ
debio
csa
inhibit
cistran
isomeras
ppias
activ
cyclophilin
sound
good
whatev
mechan
vitro
data
beg
random
control
clinic
trial
combin
plu
ribavirin
could
truli
find
fit
squar
peg
cyclic
sporin
see
hepatolog
hiv
hbv
patient
receiv
tenofovir
least
six
month
haart
retrospect
analyz
also
receiv
lamivudin
lam
lam
resist
hbeag
subject
hbv
dna
declin
median
log
copi
among
hbeag
neg
log
reduct
hbv
dna
becam
undetect
hbeag
subject
respect
tenofovir
respons
durabl
within
limit
retrospect
studi
tenofovir
show
efficaci
presum
precor
mutant
hbv
incident
bonu
haart
therapi
hiv
see
hepatolog
multicent
studi
germani
patient
acut
hepat
c
treat
week
begin
median
day
rang
infect
total
popul
svr
increas
adher
least
schedul
treatment
thu
complianc
suboptim
sustain
efficaci
higher
treat
chronic
infect
though
monotherapi
would
longer
use
chronic
infect
studi
address
whether
efficaci
would
higher
ribavirin
ad
still
sens
acut
infect
patient
given
month
achiev
spontan
clearanc
prior
initi
either
mono
combin
therapi
see
hepatolog
random
trail
daili
x
week
timeswk
plu
ribavirin
mg
daili
versu
ifn
alon
hbeag
chronic
hepat
b
benefit
observ
addit
ribavirin
week
post
treatment
combin
loss
detect
hbv
dna
hbeag
seroconvers
treatment
arm
thu
vast
major
hbv
infect
patient
respond
ifn
ribavirin
improv
outcom
see
hepatolog
